BGC0222 is a novel Irinotecan prodrug. As a PEG-cRGD conjugated derivative of Irinotecan, BGC0222 enables the slow and steady release of Irinotecan. It binds to the alphaVbeta3 target with an IC50 of 4.25 µM and has an IC50 of 58.7 µM for alphaVbeta5. BGC0222 can induce angiogenesis and demonstrates significant antitumor activity in various tumors.
Molekulargewicht:
26927.36
Formel:
C1241H2276N64O552
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
